跳到正文
ISPE iSpeak 专家博客·· 2 天前AI 评分53

ISPE博客分析清洁验证从固定阈值走向数据驱动精益改进的路径

From Arbitrary Thresholds to Data-Driven Kaizen: Cleaning Validation as a Lean Enabler

AI 导读

诺和诺德一位CIP科学家在ISPE iSpeak博客撰文,梳理清洁验证从1993年固定接受标准到HBEL与数据驱动持续改进的演进。文中把10 ppm、1/1000最小日治疗剂量和目视清洁三项传统标准视为精益标准作业的起点,并主张用HBEL和最差条件矩阵把验证资源集中到高风险产品与设备节点。

正文 · 原文

iSpeak Blog

20 November 2026

In strict Lean manufacturing taxonomy, equipment cleaning is classified as a business non-value-added activity. It does not physically transform the product in a way the patient directly pays for, yet it is non-negotiable for ensuring patient safety, preventing cross-contamination, and maintaining regulatory compliance. Because cleaning sits squarely within equipment changeover downtime, poorly designed cleaning processes and overly rigid validation frameworks act as a direct tax on plant capacity.

However, when we trace the evolution of cleaning validation—from the foundational rules introduced by Gary Fourman and Michael Mullen in their seminal 1993 Pharmaceutical Technology article (“Cleaning Validation: An Industrial Perspective”)1 to today’s science- and risk-based lifecycle approaches—we see a clear blueprint for operational excellence.

By bridging historical standardization with modern health-based exposure limits (HBELs), upfront hygienic equipment design, single-minute exchange of die (SMED) changeover principles, and ongoing lifecycle monitoring, engineering teams can systematically compress non-production idle time while strengthening compliance.

Generation 1.0: Moving from Subjectivity to Standard Work

Prior to the early 1990s, cleaning validation across the pharmaceutical industry often suffered from subjective evaluations and inconsistent site-to-site practices. Fourman and Mullen transformed cleaning validation into a structured, measurable engineering discipline by introducing three traditional acceptance criteria that quickly became global industry benchmarks:

  • The 10 parts per million (ppm) Criterion: No more than 10 ppm of the residual active ingredient from the previous batch may appear in the subsequent product.
  • The Dose Criterion: No more than 1/1000th of the minimum daily therapeutic dose of the previous product may carry over into the maximum daily dose of the following product.
  • The Visual Cleanliness Criterion: All product-contact equipment surfaces must appear visibly clean to the naked eye under defined lighting and viewing conditions.

Although not written in a Lean manufacturing context, these rules established the foundational prerequisite for any Lean system: standard work. As Lean pioneer Taiichi Ohno famously observed, where there is no standard, there can be no Kaizen (continuous improvement). By replacing subjective judgment with concrete numerical limits, the industry gained a reproducible baseline. Clear thresholds enabled engineering teams to benchmark automated clean-in-place (CIP) systems, apply error-proofing (poka-yoke) to process design, eliminate the waste of redundant justification paperwork, and reduce operator-to-operator variability across shifts. Most importantly, these standards anchored cleaning validation in the ultimate Lean definition of value: protecting the patient from cross-contamination.

Generation 2.0: Risk-Based Prioritization and HBEL Science

While the 1993 rules provided a vital historical baseline, applying arbitrary mathematical thresholds (such as a blanket 10 ppm limit) universally across diverse product portfolios can inadvertently generate operational waste. For highly soluble, low-hazard compounds, an artificially tight 10 ppm ceiling often triggers over-processing—forcing facilities into extended wash cycles, excessive water-for-injection (WFI) consumption, and costly investigations into scientifically negligible excursions. Conversely, for highly potent active pharmaceutical ingredients or compounds with specific toxicological hazards, a traditional 1/1000th dose limit may not provide an adequate margin of safety.

Modern regulatory frameworks—including International Council for Harmonisation (ICH) Q9(R1)2, ICH Q103, European Medicines Agency guidelines4, and the ISPE Baseline® Guide on Risk-Based Manufacture of Pharmaceutical Products (Second Edition)5—resolve this inefficiency by integrating traditional thresholds with science-based HBELs, such as permitted daily exposure. Aligning cleaning acceptance limits with actual pharmacological and toxicological data embodies Lean thinking: it eliminates the waste of over-cleaning low-risk products while concentrating rigorous engineering controls where patient risk genuinely resides.

At the portfolio level, regulators expect a risk-based worst-case validation strategy. In Lean terms, worst-case matrixing serves as a strategic prioritization filter, directing finite validation resources toward high-risk nodes rather than executing redundant validation runs across every product-equipment permutation:

  • Worst-Case Product Selection: Prioritizing formulations with the lowest aqueous or detergent solubility (hardest physical residues to remove), the highest potency or toxicity (lowest HBEL and matrix carryover limits), the largest batch sizes or active concentrations, allergenic profiles, and viscous or sticky excipients that resist shear forces
  • Worst-Case Equipment Selection: Targeting complex mechanical geometries (dead legs, elastomeric gaskets, instrument ports, and valve bodies), equipment trains with the largest shared product-contact surface areas, and manual cleaning operations, which inherently carry far greater human variability than automated CIP/steam-in-place (SIP) skids

When practitioners pair worst-case matrixing with Lean tools like value stream mapping, they can strip non-value-added sampling, redundant analytical testing, and repetitive protocol generation out of the validation lifecycle—accelerating new product introductions without compromising quality.

Upfront Lean Design (3P): Engineering Out the Waste

Risk matrices establish what constitutes an acceptable residue limit, but the physical cleaning process dictates how long a manufacturing line remains idle between campaigns. Cleaning cycle duration is governed by the interplay of Sinner’s Circle parameters—time, action (impingement/turbulence), concentration, and temperature (TACT)—against product residue characteristics and vessel geometry. If engineering teams treat equipment design as fixed, they are forced to compensate for poor fluid mechanics by extending wash durations, increasing chemical concentrations, and consuming excess thermal energy.

Applying Lean Production Preparation Process (3P) principles during detailed engineering attacks changeover waste before equipment ever reaches the plant floor:

  1. Hygienic Design Enablers: Selecting rotary or static spray devices matched to the soil rheology, optimizing nozzle placement to eliminate mechanical shadowing behind agitator shafts and baffles, and minimizing tank inlets, outlets, and dip tubes to simplify fluid flow paths.
  2. Early Verification at Factory Acceptance Testing (FAT): Executing rigorous spray coverage studies (such as riboflavin fluorescence testing) during FAT provides empirical proof of complete surface wetting early in the capital project lifecycle. Identifying and correcting a shadowed nozzle orientation or an un-swept port during FAT prevents costly field piping retrofits and permanently inflated CIP recipes during commercial manufacturing.

Consider a typical multi-product formulation vessel: when engineering teams eliminate redundant top-head nozzles and resolve agitator-hub shadowing during FAT, they remove the mass-transfer bottlenecks that normally require prolonged rinse phases to clear trapped detergent and product residue. Designing for cleanability upfront directly advances SMED (quick changeover) objectives on the shop floor:

  • Resource and Utility Conservation: Verified complete surface coverage minimizes the volume of purified water, WFI, chemical cleaning agents, and steam/electrical power required per CIP cycle.
  • Idle Time Compression: Faster, more effective mass transfer shortens wash and rinse steps, directly compressing non-production equipment downtime.
  • Latent Capacity Expansion: Reducing turnaround time between batches increases equipment availability, boosting overall equipment effectiveness (OEE) and unlocking additional commercial plant capacity without capital expansion.

Stage 3 Lifecycle Kaizen: Data-Driven Cycle Optimization

True continuous improvement (Kaizen) does not end once initial validation protocols (Stage 2) are signed off. When baseline design insights from FAT coverage studies are connected to Lifecycle Stage 3 Continued Process Verification (CPV), cleaning validation evolves from a static compliance snapshot into a dynamic operational feedback loop.

By leveraging inline process analytical technology (PAT)—such as final-rinse conductivity sensors, online total organic carbon (TOC) analyzers, temperature transmitters, and return-line flow/turbidity monitoring—engineering teams capture continuous performance data across hundreds of commercial cycles. Applying statistical process control (SPC) to Stage 3 CPV data allows scientists to distinguish normal batch-to-batch variability from early mechanical drift, such as a partially occluded spray nozzle or declining CIP supply pump pressure. Furthermore, empirical CPV baselines provide the regulatory justification needed to optimize conservatively padded CIP recipes—shaving unnecessary minutes and hundreds of liters of WFI off rinse phases while maintaining a robust, validated state of control.

The Lean Cleaning Validation Matrix

Lean PrincipleApplication in Modern Cleaning Validation & Process Design
Value and Risk PrioritizationAligning carryover limits with toxicological HBELs and worst-case matrices protects patient safety while eliminating over-processing and excess testing on low-risk equipment trains
Standard WorkClear numerical acceptance criteria, verified FAT spray coverage baselines, and automated CIP recipes establish highly reproducible, shift-independent changeover cycles
Waste Reduction (SMED)Hygienic vessel geometry (minimized inlets/outlets, eliminated dead legs, optimized nozzle placement) cuts WFI, detergent, utility consumption, and equipment idle time
Error Proofing (Poka-Yoke)Defined analytical limits, automated CIP parameter interlocks, and inline PAT verification eliminate the human variability inherent in manual cleaning and subjective release
Continuous Improvement (Kaizen)Combining historical validation baselines with FAT coverage insights and Stage 3 CPV trending enables ongoing recipe refinement, shorter turnaround times, and higher plant OEE

Conclusion

Fourman and Mullen’s 1993 criteria pulled pharmaceutical cleaning validation out of ambiguity and established the industry’s first measurable standard work. Today, when we evolve that historical baseline using HBEL toxicology, ICH Q9 risk-based matrixing, upfront hygienic equipment design, and data-driven Stage 3 CPV, we bridge regulatory science and Lean engineering, transforming required changeover downtime into a strategic driver of manufacturing capacity and operational excellence.

Disclaimer

The views, thoughts, and opinions expressed in this blog post belong solely to the author and are shared in a personal capacity. They do not reflect the official policy, position, or practices of the author’s current or previous employers, nor are they derived from or inspired by any proprietary processes of those organizations.

iSpeak Disclaimer

iSpeak blog posts provide an opportunity for the dissemination of ideas and opinions on topics impacting the pharmaceutical industry. Ideas and opinions expressed in iSpeak blog posts are those of the author(s) and publication thereof does not imply endorsement by ISPE.

About the Author

CIP Scientist

Novo Nordisk A/S

With over a decade of experience in the pharmaceutical industry, my focus has been on cleaning validation, cross-contamination quality risk management, and operational excellence. As...

References

  • 1

    Fourman, G. L., and M. V. Mullen. “Cleaning Validation: An Industrial Perspective.” Pharmaceutical Technology 17, no. 4 (1993): 54–60.

  • 2

    International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Harmonised Guideline: Quality Risk Management Q9(R1). Geneva: ICH, 2023.

  • 3

    International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Harmonised Tripartite Guideline: Pharmaceutical Quality System Q10. Geneva: ICH, 2008.

  • 4

    European Medicines Agency (EMA). Guideline on Setting Health Based Exposure Limits for Use in Risk Identification in the Manufacture of Different Medicinal Products in Shared Facilities (EMA/CHMP/CVMP/SWP/169430/2012). London: EMA, 2014.

  • 5

    International Society for Pharmaceutical Engineering (ISPE). ISPE Baseline® Guide: Risk-Based Manufacture of Pharmaceutical Products (Risk-MaPP) (Second Edition). North Bethesda, MD: ISPE, 2017.

来源:ISPE iSpeak 专家博客 · ispe.org

所属事件

查看事件全部
ISPE博客主张清洁验证转向HBEL与数据监控